From disease eradication efforts to advances in vaccination and maternal health, this archive tracks real progress in public health. Stories here focus on what’s working — policies, interventions, and research that are improving and extending lives around the world.
Dubbed “Calixcoca,” the treatment, developed by researchers at the Federal University of Minas Gerais, triggers an immune response that blocks cocaine and crack from reaching the brain. Last week, the project won the top prize of €500,000 at the Euro Health Innovation Awards for Latin American medicine.
The researchers from the University of Cambridge found that, on its own, the blood test could diagnose up to 30% of patients with BD, but combining it with the online psychiatric assessment significantly improved the diagnosis rate, especially in people whose diagnosis was not obvious.
Cervical cancer survival rates could improve dramatically after a major clinical trial found that adding a short course of chemotherapy before standard treatment reduces the risk of death or recurrence by 35%. Led by University College London researchers and funded by Cancer Research U.K., the trial showed 80% of women using the new approach were alive at five years, compared to 72% receiving standard treatment alone. The finding is considered the biggest advance in cervical cancer outcomes in over 20 years. Crucially, the drugs involved are already approved, widely available, and inexpensive, meaning the protocol could be adopted globally without new approvals or manufacturing delays.
For centuries, this disease has afflicted millions of people worldwide, causing pain, severe disability and social stigmatization. It is now the second neglected tropical disease (NTD) that the Southeast Asian country has eliminated following the elimination of trachoma as a public health problem in 2017.
Bioprinted skin combining all six primary skin cell types has, for the first time, been successfully grafted onto wounds in pre-clinical trials — closing them faster and with noticeably less scarring. Researchers at Wake Forest layered keratinocytes, fibroblasts, adipocytes, melanocytes, and two other cell types into a three-layer structure mirroring real skin, then watched it grow blood vessels and integrate naturally with surrounding tissue. A larger graft, roughly two inches square, worked on a pig model — a meaningful step toward the kind of scale human patients actually need. For burn survivors and others who simply don’t have enough healthy skin to donate, a lab-grown alternative made from their own cells could transform one of medicine’s most painful, limited tools into something closer to true regeneration.
The R21/Matrix-M vaccine, developed at Oxford University, is expected to offer countries a cheaper and more readily available option than the world’s first shot against the parasitic disease.
Researchers at the University of North Carolina have developed an AI model that can predict in real-time whether or not cancerous tissue has been fully removed during breast cancer surgery. The model performed as well as, or better than, human doctors.
A tooth regrowth drug has entered human clinical trials in Japan, offering a potential third option alongside dentures and implants. The treatment works by blocking USAG-1, a gene that acts as a natural brake on tooth development, freeing the body to grow new teeth on its own. Researchers confirmed the approach first in mice, then in ferrets, before moving to people, and a pediatric trial is planned for children with anodontia, a rare condition that leaves six or more teeth missing. Dr. Katsu Takahashi, who has chased this idea since 2005, hopes for regulatory approval by 2030. With oral disease affecting some 3.5 billion people worldwide, regrowing real teeth could reshape dental care far beyond Japan.
Researchers from the University of Chicago have created a new vaccine that can effectively treat these debilitating diseases in a way that doesn’t require suppressing the entire immune system and thus prevents a variety of negative side effects.
A genetically modified pig kidney kept working inside a human body for 61 days at NYU Langone Health — the longest a non-human organ has ever functioned in a person. Surgeons used a simplified approach, transplanting a kidney from a pig with just one gene edit and leaving the thymus gland attached to help the recipient’s immune system accept it. Around 100,000 Americans are on the kidney waitlist at any given time, and researchers hope pig organs could one day help close that gap. The team is now preparing for clinical trials pending FDA approval. For the thousands waiting on a kidney that may not arrive in time, this is real, tangible hope.
